Hebermin (Factor of epidérmico growth)
Characteristics of the product:
Hebermin is a healing cream that has a high effectiveness in the treatment of the cutaneous injuries, because its fundamental component is the factor of human Epidérmico Growth (FCEh). The FCEh is a peptide of 53 amino acids that stimulates the cellular proliferation. It is produced in the Center of Genetic Engineering and Biotecnologi’a (CIGB) by means of techniques of applied DNA recombination on a leavening stock transformed genetically, so that it contains the gene of the human protein under a high level of expression.
Indications of the Product:
Hebermin indicates for the treatment of burns, obtaining a sensible reduction of the time of healing, in superficial dérmicas burns as much as deep. In hypodermic burns, Hebermin also shortens to the time of evolution when obtaining a zone of granulation of more quality than it facilitates the reception of the graft. Hebermin is very useful in the treatment of ulcers by extravación of citostáticos and circulatory insufficiency, and in the prophylaxis of injuries by superficial x-ray .
Form of Presentation:
Opaque white polyethylene bottles of color with capacity for 30 and 200 gr..
Countries where the product is commercialized at the moment:
Barbuda, Bahamas, Belize, Bielorrusia, Bolivia, China, Colombia, Cuba, El Salvador, Laos, Lituania, Latvia, Nicaragua, Peru, Rep. Dominican, Rumania, Santa Lucia, The Ukraine, Uruguay, Vietnam .
A must read on Hebermin:
Manufacturer of Hebermin:
Article on wound healing:
REGULATION OF WOUND HEALING BY PEPTIDE GROWTH FACTORS
Growth factors are messenger peptides secreted from a number of cell types integral to the repair mechanism. In general, growth factors are mitogens and chemoattractants. They show a remarkable specificity for cell types, acting selectively to induce cells into the wound environment in an orderly sequence, beginning with neutrophils, followed by macrophages, fibroblasts, and endothelial cells. As previously stated, the functions of these cells in wound healing include removal of cellular debris, leading to the formation of granulation tissue and its replacement with collagen and subsequently, mature scar tissue. Growth factors are also released from blood on coagulation and subsequently are contributed by macrophages and probably by fibroblasts.
To date, the following growth factors have been shown to play a pivotal role in wound healing:
1.Transforming growth factor beta (TGF-b) is a potent stimulator of the synthesis of matric proteins, such as collagen and fibronectin, and of glycosaminoglycans. It is present in high concentration in blood platelets and is released instantaneously into the wound at the site of injury. Multiple forms of TGF-b and the TGF-b receptor exist; these may generate a complex and diverse range of interacting signals on matrix, mesenchyme, and endothelial cells, some of which are inhibitory and some of which are stimulatory.
2.Platelet-derived growth factor (PDGF) has a more restricted target-cell specificity in comparison with other growth factors, but it is a major serum mitogen, also released from the a-granules of platelets, inducing fibroblast proliferation, matrix production, and maturation of connective tissue. Its particular attributes are effects on cell surface (cytoskeleton) motility, mainly directed at smooth muscle cells and fibroblasts.
3.Basic fibroblast growth factor (b-FGF) has its main stimulatory effect on the growth and differentiated function of fibroblasts and on the proliferation of vascular smooth muscle cells and endothelial cells. Therefore it has a major function as an ‘angiogenesis peptide”.
4.Epidermal growth factor (EGF) and its homologue, transforming growth factor alpha (TGF-a), generally stimulate cell proliferation by binding to the EGF receptor in a variety of tissue types. They are also released from a granules of platelets.
Numerous other growth factors and cytokines have been proved to be, or are likely to be present in wounds. These include insulin-like growth factor (IGF), platelet derived endothelial cell growth factor (PDECGF), vascular endothelial growth factor (VEGF), heparin binding epidermal growth factor (HG-EGF), and granulocyte monocyte colony stimulating factor (GMCFS). Their role(s) are still uncertain. The situation is further confused by the fact that many growth factors, notably TGF-b, PDGF, and IGF exist as multiple ‘isoforms”. Growth factor activity is also modulated by association with binding proteins, and depends upon the availability and type of receptor(s) present. Thus, for example, IGF1 is transferred from blood and local sites of production to its cellular targets via a sequence of binding proteins, whose affinities are modulated by the pH of the wound environment. Alterations in the levels of binding proteins, and elevations of IGF antagonists have been found in situations associated with defective repair, including diabetes, malnutrition, uraemia, and jaundice.
The function of growth factor receptors and of post-receptor signalling pathways is also important. In vitro, high levels of several growth factors have been shown to reduce (down-regulate) expression of the relevant receptor at the cell surface. As a result, increasing levels of growth factor are ultimately associated with decreased cellular responses.
The pattern of growth factor expression in human wounds is being described by the techniques of immunoassay of wound fluid and of immunohistochemistry of biopsies. Unfortunately, these methods recognize antigenic determinants on the growth factor molecules, not their biological activity. Thus, for example, chronic venous ulcers have been found by Ferguson and colleagues to contain high levels of growth factors, including FGF, PDGF, and TGF-b, predominantly distributed in the fibrin cuffs around the blood vessels. It is not known whether these growth factors are biologically active, and if so whether they are sequestered or able to diffuse, or whether the appropriate receptors are expressed on adjacent wound cells.
The early response to injury
Thrombin, formed from the clotting cascade, stimulates the release of growth factors from a-granules of platelets. TGF-b, PDGF, and EGF are released locally and are chemotactic for both macrophages and fibroblasts. Macrophages play a critical role in subsequent events because they secrete a large repertoire of peptides involved in wound-healing mechanisms. These peptides include TGF-b, PDGF, b-FGF, EGF, TGF-a, and tumour necrosis factor (TNF). Phenotypic changes occur in macrophages as the wound matures, as evidenced by variation in their abilities to secrete peptides under basal or stimulated conditions. This modification in synthetic activity presumably leads to differential production of matrix, collagen, or ground substance at a particular time in the maturation of the wound. In addition, growth factors such as b-FGF have a strong influence on cellular movement within the wound, stimulating chemotaxis followed by synthetic activity when cells are positioned to deliver their products. PDGF may be a multifunctional ‘first signal” peptide at the site of injury, being the first messenger stimulating fibroblast proliferation.
Therapeutic Action: Factor of recombinant epidérmico growth human DNA.
Dosage: After cleaning the injuries a fine cream layer is applied directly on these, the dose is determined by the extension of the injuries. In extensive burns the application is recommended, along with the treatment, in alternating days. Also it can be used every 4 days with good results. In infected injuries one requires the local cleaning and the complementary treatment with antibiotics.
Contraindications: It does not have known contraindications, although hypersensitivity or allergy to sulfonamides would not have to be administered to patients with. It does not have to be used in women with pregnancy upon maturity nor in new born during the first month of life, by the adverse effects of the sulfadiacina of silver.
Presentations: Package containing 200 cream g for topical use that contains: 2 mg of Factor of Recombinant Human Epidérmico Growth; 2 g (1%) of Sulfadiacina de Plata in hidrofílico excipiente.
So, what does this mean for scar sufferers?
It means that Epidemal Growth Factors can be used in processes that require healing or tissue regeneration, such as after any type of surgery, injury, burns, chemical peels, TCA CROSS, excisions etc…
and in theory should not only help heal the wounds faster, but increase cellular activity … leaving us with perfect skin??????????